Amicus Therapeutics Inc. (NASDAQ:FOLD)‘s stock had its “outperform” rating restated by research analysts at Cowen and Company in a report issued on Wednesday. They presently have a $12.00 price objective on the biopharmaceutical company’s stock, down from their previous price objective of $15.00. Cowen and Company’s price target points to a potential upside of 84.33% from the company’s current price.

A number of other equities research analysts have also commented on FOLD. JPMorgan Chase & Co. reiterated an “overweight” rating and issued a $11.00 target price (down previously from $12.00) on shares of Amicus Therapeutics in a research report on Wednesday. Robert W. Baird reiterated a “hold” rating and issued a $7.00 target price (down previously from $9.00) on shares of Amicus Therapeutics in a research report on Tuesday. Leerink Swann reiterated a “buy” rating and issued a $17.00 target price on shares of Amicus Therapeutics in a research report on Tuesday, November 8th. Zacks Investment Research upgraded Amicus Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, October 25th. Finally, Chardan Capital reiterated a “buy” rating and issued a $16.00 target price (up previously from $15.00) on shares of Amicus Therapeutics in a research report on Tuesday. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and six have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $11.31.

Analyst Recommendations for Amicus Therapeutics (NASDAQ:FOLD)

Shares of Amicus Therapeutics (NASDAQ:FOLD) opened at 6.51 on Wednesday. Amicus Therapeutics has a 52-week low of $4.98 and a 52-week high of $11.02. The company’s market cap is $926.54 million. The stock’s 50 day moving average is $7.82 and its 200 day moving average is $6.97.

Amicus Therapeutics (NASDAQ:FOLD) last issued its earnings results on Monday, November 7th. The biopharmaceutical company reported ($0.33) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.34) by $0.01. The firm earned $2.10 million during the quarter, compared to analysts’ expectations of $1.71 million. Equities analysts forecast that Amicus Therapeutics will post ($1.38) EPS for the current year.

COPYRIGHT VIOLATION WARNING: “Amicus Therapeutics’ (FOLD) Outperform Rating Reiterated at Cowen and Company” was published by Daily Political and is the propert of of Daily Political. If you are viewing this piece of content on another publication, it was illegally stolen and reposted in violation of US & international copyright and trademark law. The correct version of this piece of content can be read at http://www.dailypolitical.com/2016/11/30/amicus-therapeutics-fold-outperform-rating-reiterated-at-cowen-and-company.html.

In other news, insider Hung Do sold 25,000 shares of the stock in a transaction that occurred on Tuesday, September 6th. The stock was sold at an average price of $7.00, for a total transaction of $175,000.00. Following the transaction, the insider now owns 583,453 shares in the company, valued at approximately $4,084,171. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CFO William D. Baird III sold 20,500 shares of the stock in a transaction that occurred on Tuesday, September 20th. The shares were sold at an average price of $8.00, for a total value of $164,000.00. Following the transaction, the chief financial officer now owns 56,450 shares in the company, valued at approximately $451,600. The disclosure for this sale can be found here. Insiders own 3.40% of the company’s stock.

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. UBS Group AG raised its position in shares of Amicus Therapeutics by 37.7% in the first quarter. UBS Group AG now owns 88,282 shares of the biopharmaceutical company’s stock worth $746,000 after buying an additional 24,155 shares during the period. Squarepoint Ops LLC increased its position in Amicus Therapeutics by 101.9% in the first quarter. Squarepoint Ops LLC now owns 83,600 shares of the biopharmaceutical company’s stock valued at $706,000 after buying an additional 42,200 shares in the last quarter. GW&K Investment Management LLC increased its position in Amicus Therapeutics by 12.3% in the second quarter. GW&K Investment Management LLC now owns 468,708 shares of the biopharmaceutical company’s stock valued at $2,559,000 after buying an additional 51,273 shares in the last quarter. Candriam Luxembourg S.C.A. increased its position in Amicus Therapeutics by 14.5% in the second quarter. Candriam Luxembourg S.C.A. now owns 709,900 shares of the biopharmaceutical company’s stock valued at $3,876,000 after buying an additional 90,000 shares in the last quarter. Finally, Bank of New York Mellon Corp increased its position in Amicus Therapeutics by 19.8% in the second quarter. Bank of New York Mellon Corp now owns 649,235 shares of the biopharmaceutical company’s stock valued at $3,545,000 after buying an additional 107,215 shares in the last quarter.

About Amicus Therapeutics

Amicus Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of therapies to treat a range of rare and orphan diseases. Its lead product candidate, migalastat HCl (Galafold), is an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease, which is a type of lysosomal storage disorder (LSD).

5 Day Chart for NASDAQ:FOLD

Receive News & Ratings for Amicus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.